BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29978802)

  • 1. [Research Advances in CIMAvax-EGF for Non-small-cell Lung Cancer].
    Zhang JY; Zhu L; Yang HK; Chen F
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Jun; 40(3):411-414. PubMed ID: 29978802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy.
    Rodríguez PC; Rodríguez G; González G; Lage A
    MEDICC Rev; 2010; 12(1):17-23. PubMed ID: 20387330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CIMAvax-EGF: Toward long-term survival of advanced NSCLC.
    Saavedra D; Neninger E; Rodriguez C; Viada C; Mazorra Z; Lage A; Crombet T
    Semin Oncol; 2018 Jan; 45(1-2):34-40. PubMed ID: 30318082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.
    Rodriguez PC; Popa X; Martínez O; Mendoza S; Santiesteban E; Crespo T; Amador RM; Fleytas R; Acosta SC; Otero Y; Romero GN; de la Torre A; Cala M; Arzuaga L; Vello L; Reyes D; Futiel N; Sabates T; Catala M; Flores YI; Garcia B; Viada C; Lorenzo-Luaces P; Marrero MA; Alonso L; Parra J; Aguilera N; Pomares Y; Sierra P; Rodríguez G; Mazorra Z; Lage A; Crombet T; Neninger E
    Clin Cancer Res; 2016 Aug; 22(15):3782-90. PubMed ID: 26927662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF.
    Fernández Lorente A; Acosta Brooks S; Neninger Vinageras E; Barroso Alvarez Mdel C; Wilkinson Brito B; Troche Concepción M; Martínez Pérez LB; Viada González CE; Crespo Diaz T; Casacó Parada AR
    World J Surg Oncol; 2013 Oct; 11():275. PubMed ID: 24127898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.
    Crombet Ramos T; Rodríguez PC; Neninger Vinageras E; Garcia Verdecia B; Lage Davila A
    Expert Rev Vaccines; 2015; 14(10):1303-11. PubMed ID: 26295963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
    Tagliamento M; Rijavec E; Barletta G; Biello F; Rossi G; Grossi F; Genova C
    Expert Opin Biol Ther; 2018 Jul; 18(7):829-835. PubMed ID: 29936901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule.
    Popa X; García B; Fuentes KP; Huerta V; Alvarez K; Viada CE; Neninger E; Rodríguez PC; González Z; González A; Crombet T; Mazorra Z
    Oncoimmunology; 2020 May; 9(1):1762465. PubMed ID: 32923124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer.
    Sanchez L; Muchene L; Lorenzo-Luaces P; Viada C; Rodriguez PC; Alfonso S; Crombet T; Neninger E; Shkedy Z; Lage A
    Semin Oncol; 2018 Jan; 45(1-2):52-57. PubMed ID: 30318084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.
    Ruiz R; Hunis B; Raez LE
    Curr Oncol Rep; 2014 Sep; 16(9):400. PubMed ID: 25030654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
    García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
    Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
    Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
    J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.
    Saavedra D; Crombet T
    Front Immunol; 2017; 8():269. PubMed ID: 28348561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of CIMAvax-EGF administered in community polyclinics.
    Ortiz Carrodeguas RA; Lorenzo Monteagudo G; Guerra Chaviano PP; Álvarez Montané I; Salomón Saldívar EE; Lobaina Lambert L; Camacho Sosa K; Bermúdez Pino R; Blanco Mustelier P; Valdés Rodríguez E; González Piloto S; Guerra de la Vega A; Valdés Sánchez L; Montes De Santis A; Parra Zabala J; Viada González C; Calvo Aguilera N; Saavedra Hernández D; Santos Morales O; Crombet Ramos T
    Front Oncol; 2023; 13():1287902. PubMed ID: 38304035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer.
    Neninger E; Verdecia BG; Crombet T; Viada C; Pereda S; Leonard I; Mazorra Z; Fleites G; González M; Wilkinson B; González G; Lage A
    J Immunother; 2009 Jan; 32(1):92-9. PubMed ID: 19307998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active immunotherapy for non-small-cell lung cancer: moving toward a reality.
    Perez CA; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1599-605. PubMed ID: 21999133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cuban vaccine tested in Canadian trial.
    Randal J
    J Natl Cancer Inst; 2000 Jul; 92(13):1037. PubMed ID: 10880544
    [No Abstract]   [Full Text] [Related]  

  • 18. Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients.
    Lorenzo-Luaces P; Sanchez L; Saavedra D; Crombet T; Van der Elst W; Alonso A; Molenberghs G; Lage A
    BMC Cancer; 2020 Aug; 20(1):772. PubMed ID: 32807114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma.
    Cheng JY; Kananathan R
    Hum Vaccin Immunother; 2012 Dec; 8(12):1799-801. PubMed ID: 22906936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario.
    Flores Vega YI; Páramo González DL; Alsina Sarmiento SC; Alsina Tul LE; Inguanzo Valdés IB; Rodríguez Machado J; Elejalde Larrinaga Á; Flores Rodríguez JE; Lamadrid García J; Corrales Otero D; Ropero Toirac R; Crombet Ramos T; Gracia Medina EA
    J Cancer; 2023; 14(5):874-879. PubMed ID: 37056397
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.